[Cardiovascular risk in systemic inflammatory diseases]

G Ital Cardiol (Rome). 2013 Jul-Aug;14(7-8):517-25. doi: 10.1714/1308.14460.
[Article in Italian]

Abstract

Systemic inflammatory diseases are associated with increased cardiovascular morbidity and mortality. The link between inflammatory and cardiovascular diseases can be attributed to the coexistence of classical risk factors and inflammatory mechanisms activated during systemic inflammatory diseases involving the immune system. Unfavorable metabolic effects of anti-inflammatory drugs can also contribute to increase cardiovascular risk. Yet, clinical implications of these findings are not entirely clear, and deeper knowledge and awareness of cardiac involvement in inflammatory diseases are necessary. The aim of this review is to summarize cardiac involvement in systemic inflammatory diseases and to identify aspects where evidence is currently lacking that would deserve further investigation in the future.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / prevention & control
  • Coronary Disease / epidemiology
  • Coronary Disease / etiology
  • Humans
  • Inflammation / complications*
  • Inflammation / drug therapy
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy
  • Psoriasis / complications
  • Psoriasis / drug therapy
  • Risk Factors
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha